MA31920B1 - 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation - Google Patents

4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation

Info

Publication number
MA31920B1
MA31920B1 MA32921A MA32921A MA31920B1 MA 31920 B1 MA31920 B1 MA 31920B1 MA 32921 A MA32921 A MA 32921A MA 32921 A MA32921 A MA 32921A MA 31920 B1 MA31920 B1 MA 31920B1
Authority
MA
Morocco
Prior art keywords
thioaryl
cyano
dihydropyrimidinone
prevention
treatment
Prior art date
Application number
MA32921A
Other languages
Arabic (ar)
English (en)
Inventor
Nussbaum Franz Von
Dagmar Karthaus
Sonja Anlauf
Martina Delbeck
Volkhart Min-Jian Li
Daniel Meibom
Klemens Lustig
Jens Schamberger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31920(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102007061766A external-priority patent/DE102007061766A1/de
Priority claimed from DE102008022521A external-priority patent/DE102008022521A1/de
Priority claimed from DE102008052013A external-priority patent/DE102008052013A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31920B1 publication Critical patent/MA31920B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE : DE NOUVEAUX DÉRIVÉS DE 4-(4-CYANO-2-THIOARYLE)-DIHYDROPYRIMIDINE-2-ONE : DES PROCÉDÉS POUR LEUR FABRICATION ; LEUR UTILISATION SEULS OU EN COMBINAISONS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES ET LEUR UTILISATION POUR LA FABRICATION DE MÉDICAMENTS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES, EN PARTICULIER POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES DES POUMONS ET DU SYSTÈME CARDIOVASCULAIRE.
MA32921A 2007-12-20 2010-06-16 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation MA31920B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102007061766A DE102007061766A1 (de) 2007-12-20 2007-12-20 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008022521A DE102008022521A1 (de) 2008-05-07 2008-05-07 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102008052013A DE102008052013A1 (de) 2008-10-17 2008-10-17 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
PCT/EP2008/010411 WO2009080199A1 (fr) 2007-12-20 2008-12-09 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation

Publications (1)

Publication Number Publication Date
MA31920B1 true MA31920B1 (fr) 2010-12-01

Family

ID=40394273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32921A MA31920B1 (fr) 2007-12-20 2010-06-16 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation

Country Status (38)

Country Link
US (3) US8288402B2 (fr)
EP (1) EP2234985B1 (fr)
JP (1) JP5519526B2 (fr)
KR (2) KR101712786B1 (fr)
CN (2) CN101903356B (fr)
AR (1) AR069765A1 (fr)
AT (1) ATE548355T1 (fr)
AU (1) AU2008340733B9 (fr)
BR (1) BRPI0821027B8 (fr)
CA (1) CA2709786C (fr)
CL (1) CL2008003691A1 (fr)
CO (1) CO6280490A2 (fr)
CR (1) CR11472A (fr)
CY (1) CY1112813T1 (fr)
DK (1) DK2234985T3 (fr)
DO (1) DOP2010000165A (fr)
EC (1) ECSP10010216A (fr)
ES (1) ES2382143T3 (fr)
HR (1) HRP20120457T1 (fr)
IL (2) IL205742A (fr)
JO (1) JO2756B1 (fr)
MA (1) MA31920B1 (fr)
MX (1) MX2010006033A (fr)
MY (1) MY150285A (fr)
NZ (1) NZ586263A (fr)
PE (1) PE20091429A1 (fr)
PL (1) PL2234985T3 (fr)
PT (1) PT2234985E (fr)
RS (1) RS52270B (fr)
RU (1) RU2497813C2 (fr)
SG (2) SG10201604819TA (fr)
SI (1) SI2234985T1 (fr)
SV (1) SV2010003581A (fr)
TN (1) TN2010000288A1 (fr)
TW (1) TWI455715B (fr)
UY (1) UY31526A1 (fr)
WO (1) WO2009080199A1 (fr)
ZA (1) ZA201004239B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2157092A4 (fr) * 2007-04-11 2011-04-13 Ajinomoto Kk Remède pour des diabètes
HRP20120457T1 (hr) * 2007-12-20 2012-06-30 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
DE102009016553A1 (de) * 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
GB201004178D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
AU2012300274B2 (en) 2011-08-26 2017-06-29 Sanford-Burnham Medical Research Institute HIV replication inhibitors
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
WO2014110200A1 (fr) 2013-01-10 2014-07-17 Zisman Lawrence S Inhibiteurs de kinase non sélectifs
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) * 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) * 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) * 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) * 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016050835A2 (fr) * 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Inhibiteurs sélectifs de l'élastase neutrophilique pour traiter des états de douleur neuropathique et de douleur chronique comprenant une composante neuropathique
CA2980071A1 (fr) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Procede de production de (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
US20180110774A1 (en) * 2015-04-28 2018-04-26 Stc. Unm Compositions and methods for treatment of pulmonary hypertension
WO2017081044A1 (fr) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryle)-dihydropyrimidinones destinées au traitement de plaies chroniques
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US9856232B1 (en) 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives
EP3765059A4 (fr) * 2018-03-12 2022-01-12 Yale University Procédés de traitement ou de prévention du syndrome de détresse respiratoire aiguë
KR20210002573A (ko) 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
CA3151997A1 (fr) * 2019-08-23 2021-03-04 Ph Pharma Co., Ltd. Utilisation d'un inhibiteur de l'elastase neutrophile dans les maladies pulmonaires
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CN111978179A (zh) * 2020-08-27 2020-11-24 青岛科技大学 一种6-羟基己酸酯的合成方法
WO2022076881A1 (fr) * 2020-10-09 2022-04-14 The Regents Of The University Of California Méthodes de traitement de la maladie d'alzheimer à l'aide d'inhibiteurs d'époxyde hydrolase soluble à liaison étroite lents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT42077A (en) * 1985-06-03 1987-06-29 Squibb & Sons Inc Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
US4738965A (en) * 1987-02-03 1988-04-19 Institut Organischskogo Sinteza Akademii Nauk Ssr 2-oxo-4-(2'-difluoromethylthiophenyl)-5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
WO1997035855A1 (fr) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement de lesions du systeme nerveux central
ATE307129T1 (de) * 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
MXPA05002644A (es) * 2002-09-10 2005-09-20 Bayer Healthcare Ag Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
CA2498052C (fr) 2002-09-10 2011-05-17 Bayer Healthcare Ag Derives heterocycliques
GB2392910A (en) * 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
JP4825195B2 (ja) * 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
ES2394177T3 (es) * 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
WO2005097759A1 (fr) * 2004-03-29 2005-10-20 Merck & Co., Inc. Utilisation de diaryltriazoles comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0520743D0 (en) 2005-10-12 2005-11-23 Argenta Discovery Ltd Compounds and their use
DK2024367T3 (da) 2006-05-04 2011-01-03 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
HRP20120457T1 (hr) * 2007-12-20 2012-06-30 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
DE102008022521A1 (de) * 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102009016553A1 (de) * 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung

Also Published As

Publication number Publication date
JP5519526B2 (ja) 2014-06-11
HK1183018A1 (en) 2013-12-13
TN2010000288A1 (en) 2011-11-11
JO2756B1 (en) 2014-03-15
CN103204815B (zh) 2015-01-28
CR11472A (es) 2010-11-12
HRP20120457T1 (hr) 2012-06-30
KR20160099733A (ko) 2016-08-22
HK1146485A1 (en) 2011-06-10
IL235754A (en) 2016-06-30
EP2234985A1 (fr) 2010-10-06
US20110034433A1 (en) 2011-02-10
DOP2010000165A (es) 2010-07-31
US20150045344A1 (en) 2015-02-12
AU2008340733B2 (en) 2014-01-30
TW200940063A (en) 2009-10-01
BRPI0821027B8 (pt) 2021-05-25
PL2234985T3 (pl) 2012-08-31
MX2010006033A (es) 2010-07-16
KR101649381B1 (ko) 2016-08-19
CN101903356B (zh) 2013-05-22
US8288402B2 (en) 2012-10-16
RS52270B (sr) 2012-10-31
CY1112813T1 (el) 2016-02-10
KR101712786B1 (ko) 2017-03-06
UY31526A1 (es) 2009-08-03
BRPI0821027A2 (pt) 2015-06-16
CO6280490A2 (es) 2011-05-20
WO2009080199A1 (fr) 2009-07-02
NZ586263A (en) 2012-06-29
ATE548355T1 (de) 2012-03-15
US8889700B2 (en) 2014-11-18
KR20100098710A (ko) 2010-09-08
CA2709786C (fr) 2016-07-05
TWI455715B (zh) 2014-10-11
RU2010129724A (ru) 2012-01-27
SI2234985T1 (sl) 2012-06-29
US9174997B2 (en) 2015-11-03
SV2010003581A (es) 2011-02-21
AU2008340733A1 (en) 2009-07-02
ZA201004239B (en) 2011-10-26
ES2382143T3 (es) 2012-06-05
DK2234985T3 (da) 2012-06-25
IL205742A0 (en) 2010-11-30
MY150285A (en) 2013-12-31
JP2011506503A (ja) 2011-03-03
SG10201604819TA (en) 2016-07-28
IL205742A (en) 2014-12-31
AU2008340733B9 (en) 2014-03-06
PE20091429A1 (es) 2009-09-26
CN101903356A (zh) 2010-12-01
ECSP10010216A (es) 2010-07-30
SG186679A1 (en) 2013-01-30
US20140045802A1 (en) 2014-02-13
RU2497813C2 (ru) 2013-11-10
CN103204815A (zh) 2013-07-17
EP2234985B1 (fr) 2012-03-07
CL2008003691A1 (es) 2010-02-12
CA2709786A1 (fr) 2009-07-02
AR069765A1 (es) 2010-02-17
BRPI0821027B1 (pt) 2020-11-10
PT2234985E (pt) 2012-05-17

Similar Documents

Publication Publication Date Title
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
EP1904111A4 (fr) Compositions et procédés pour diminuer l'expression de microarn pour le traitement de la néoplasie
MA49368B1 (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1799269A4 (fr) Oligoribonucléotides et procédés d'utilisation associés pour le traitement de l'alopécie, des insuffisances rénales aiguës et d'autres maladies
EP2209371A4 (fr) Compositions et procédés pour le traitement de la rétinopathie diabétique
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
WO2007109236A3 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
MA31535B1 (fr) (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine
ATE448232T1 (de) Substituierte heterozyklen
MA27794A1 (fr) Dihydroquinazolines substituees a proprietes antivirales
SG171599A1 (en) Blood group antigens of different types for diagnostic and therapeutic applications
EP2069377A4 (fr) Procédés et compositions pour le traitement de maladies et de troubles de la peau
EP2139460A4 (fr) Compositions et procédés permettant le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et des maladies neurologiques apparentées
JO2645B1 (en) Vehicles
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA30039B1 (fr) Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires
MA33290B1 (fr) Pipéridines substituées
DE502006007526D1 (de) Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
MA33291B1 (fr) Pipéridines substituées